Vaxcyte recently completed enrollment for three Phase 3 adult clinical trials of its VAX-31 pneumococcal vaccine candidate, along with a Phase 2 VAX-31 infant study, and outlined plans to start a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results